ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.650,03
0,00%
S&P 500
5.307,01
-0,27%
US Dollar vs BRL
5,1557
0,06%
Bitcoin
69.920,52
1,18%
Brent Oil
82,295
0,94%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) Notícias

MRUS

Merus NV (MRUS)

Merus NV
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MRUS
DataHoraFonteTítuloCódigoCompanhia
13/05/202409:00GlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
10/05/202417:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
09/05/202417:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
09/05/202417:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
08/05/202417:15GlobeNewswire Inc.Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
08/05/202409:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
06/05/202417:05GlobeNewswire Inc.Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACNASDAQ:MRUSMerus NV
08/04/202413:00GlobeNewswire Inc.Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024NASDAQ:MRUSMerus NV
03/04/202409:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:MRUSMerus NV
06/03/202410:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:MRUSMerus NV
05/03/202418:30GlobeNewswire Inc.Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionNASDAQ:MRUSMerus NV
04/03/202410:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma ConferenceNASDAQ:MRUSMerus NV
28/02/202418:55Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:MRUSMerus NV
28/02/202418:15GlobeNewswire Inc.Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
14/02/202418:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRUSMerus NV
31/01/202410:00GlobeNewswire Inc.Merus to Participate in Upcoming Investor ConferencesNASDAQ:MRUSMerus NV
15/12/202321:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
02/12/202322:40GlobeNewswire Inc.Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
26/11/202313:05GlobeNewswire Inc.Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
02/11/202317:12GlobeNewswire Inc.Merus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
02/11/202317:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRUSMerus NV
23/10/202308:30GlobeNewswire Inc.Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerNASDAQ:MRUSMerus NV
15/10/202320:58GlobeNewswire Inc.Merus Announces Business Update Conference CallNASDAQ:MRUSMerus NV
06/10/202310:32GlobeNewswire Inc.Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
11/08/202310:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
09/08/202322:53GlobeNewswire Inc.Merus Announces Pricing of Public Offering of Common SharesNASDAQ:MRUSMerus NV
09/08/202317:01GlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
07/08/202317:26GlobeNewswire Inc.Merus Announces Financial Results for the Second Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
28/07/202309:00GlobeNewswire Inc.Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023NASDAQ:MRUSMerus NV
05/07/202317:01GlobeNewswire Inc.Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug AdministrationNASDAQ:MRUSMerus NV
 Apresentando as notícias mais relevantes sobre:NASDAQ:MRUS

Seu Histórico Recente

BIT
P1VC60
NLBNPIT1VC60 20991231 11...
COIN
FORTUSD
Forta
EU
EZWTR
EN CDP W EZ EW D5 PERCENT
ASX
NCOR
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados